The current system for classifying patients with heart failure (HF) is dependent upon the confirmation of left ventricular ejection fraction (LVEF), a measurement of the heart’s ability to pump blood from the left ventricle. While patients with HF can be identified through the use of electronic medical records, the data on LVEF is oftentimes unavailable. […]
Congratulations to Dr. Padma Kaul and her team on being awarded a Spring 2023 CIHR Project Grant for the Diabetes and Cancer Outcomes in a Real-world Setting (DISCOURSE) Study. Cancer is becoming the major cause of hospitalization and death among people with diabetes. Given that they may be at a higher risk of developing cancer, there […]
Although many severe outcomes associated with COVID-19 have lessened with each successive wave, a recent study reveals that there is a persistent increased risk for cardiovascular hospitalization, especially among younger men between the ages of 18 and 65. This retrospective cohort study utilized Ontario administrative health databases to analyze data from adults who had at least one […]
It is important to account for sex and gender in randomized clinical trials (RCTs), as these factors can directly impact how individuals experience health conditions and respond to treatment. Sex is defined by biological characteristics, such as hormones, gene expression, and anatomy, whereas gender is a construct based on the social, environmental, cultural, and behavioral […]
The Spring 2023 issue of the Canadian Cardiac Chronicle newsletter is now available! Highlights from this issue include: Read and subscribe to the newsletter here.
Current guidelines recommend quadruple therapy, consisting of four drugs: angiotensin receptor-neprilysin inhibitors (ARNis), sodium-glucose cotransporter-2 inhibitor (SGLT2is), mineralocorticoid receptor antagonists (MRAs), and beta blockers (BBs), for the management of patients with heart failure (HF) and reduced ejection fraction (HFrEF), a condition in which the heart is unable to pump out blood effectively. However, even before […]
Frailty is a state of reduced physiological capacity across multiple body systems that increases vulnerability and adverse health outcomes in older adults. While frailty is a known key contributing factor to morbidity and death in patients with heart failure (HF), the link between frailty and health status is not well understood in patients with HF […]
We are pleased to share the 2022 CVC Annual Report! The theme of this year’s report – Patient Centered. Data Driven. – illustrates the many ways that the CVC’s extensive body of research utilizes data to inform patient care and improve outcomes for those with cardiovascular disease. In a world where the volume, velocity, and variety of […]
A pharmaco-invasive strategy that halved the dose of tenecteplase in older ST-elevation myocardial infarction (STEMI) patients resulted in better reperfusion than primary percutaneous coronary intervention (PCI). Reperfusion was measured by electrocardiographic data in the ECG core laboratory at the Canadian VIGOUR Centre (CVC), University of Alberta (U of A), and is a key component of […]
